Gene Editing Will Not Become the Cure for Everyone: Comparing the Cost of Lifelong Insulin Therapy to Gene-Edited Cell Transplants

Introduction

Type 1 diabetes (T1D) is a lifelong autoimmune condition affecting around 9.5 million people globally. It requires continuous insulin therapy to maintain blood glucose levels and prevent life-threatening complications. Despite advancements in insulin delivery and glucose monitoring, insulin remains a lifelong management tool—not a cure.

In contrast, gene-edited cell transplants represent a promising potential breakthrough. By using gene editing to engineer insulin-producing beta cells, these therapies aim to restore natural insulin production, potentially eliminating the need for daily injections. But as promising as this sounds, the high cost and clinical complexity of these therapies raise an important question:

Can gene-edited cell therapy ever become a practical cure for most people with Type 1 diabetes?

Related Article:

Type 1 diabetes occurs in approx. 9.5 million people. Gene editing will not become the cure for everyone. Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression.
https://www.nejm.org/doi/full/10.1056/NEJMoa2503822

---

Lifelong Insulin Therapy: A 30-Year Cost Estimate

In both the United States and Germany, insulin therapy is the standard of care for Type 1 diabetes, but the costs vary dramatically depending on the healthcare system.

Here's a breakdown comparing the estimated lifetime cost of insulin therapy (30 years) versus the cost of a gene-edited cell transplant for diabetes (typically Type 1).

United States Cost Estimates (30 Years)

Expense Category	Estimated Annual Cost	30-Year Total
Insulin (modern analogs)	$3,000 – $6,000	$90,000 – $180,000
Supplies (pens, pumps, CGMs)	$2,000 – $5,000	$60,000 – $150,000
Doctor visits + lab monitoring	$1,000 – $2,000	$30,000 – $60,000
Total (30 years)		$180,000 – $390,000

Germany Cost Estimates (30 Years) Germany’s healthcare system covers the majority of medical expenses under statutory health insurance (GKV), resulting in significantly lower out-of-pocket costs. Expense Category     Estimated Annual Cost (€)     30-Year Total (€) Insulin         €1,500 – €3,000     €45,000 – €90,000 Devices & Supplies     €1,000 – €2,500     €30,000 – €75,000 Consultations & Lab Tests     €500 – €1,000     €15,000 – €30,000 Total (30 years)     €90,000 – €195,000
Patient out-of-pocket expenses in Germany are typically limited to approximately €3,000 – €10,000 over a lifetime, thanks to insurance regulations and co-pay caps.
Gene-Edited Cell Transplants: A High-Tech, High-Cost Hope Gene-edited cell transplants involve modifying stem cells to become insulin-producing beta cells. These cells are then implanted into the patient, potentially restoring insulin independence. Some experimental approaches aim to avoid lifelong immunosuppression, a major barrier in traditional cell transplant therapies. However, these therapies are still in development or early approval stages, and costs remain extremely high. Expense Category     Estimated Cost (Germany / U.S.) Gene-edited cell therapy     €200,000 – €800,000 / $300,000 – $2,000,000 Hospitalization and follow-up care     €10,000 – €50,000 Immunosuppressive medications (if needed)     €5,000 – €20,000 Total Estimated Cost     €215,000 – €870,000 / $320,000 – $2.1 million These figures may vary based on individual clinical needs, insurance coverage, and how the therapy is administered. In Germany, new high-cost treatments undergo formal cost-effectiveness reviews before being covered by public insurance.

What Justifies the High Cost of Gene-Edited Therapies? Several factors explain the high price tag: Research and Development Costs Developing gene-edited therapies often involves over a decade of research and clinical trials, with estimated total development costs exceeding €1 billion. Complex Manufacturing These therapies involve highly controlled, lab-grown stem cells modified with technologies like CRISPR. Unlike pills or standard biologics, they require advanced bioengineering and cannot be mass-produced easily. Small Patient Population Type 1 diabetes affects fewer people than Type 2, and not all T1D patients are eligible for advanced therapies. This limits economies of scale and keeps per-patient costs high. Potential for Long-Term Remission or Cure The upfront cost reflects the potential long-term benefit. A successful cell transplant could eliminate the need for lifelong insulin therapy, which itself has high cumulative costs. Long-Term Monitoring and Immune Modulation Some approaches still require immune suppression or encapsulation devices to protect transplanted cells, which adds to both complexity and cost. Regulatory and Safety Requirements Advanced therapies face intense scrutiny for safety, and companies price in the cost of long-term follow-up studies, adverse event monitoring, and liability risks.
Why Gene Editing Will Not Be the Cure for Everyone Despite its promise, gene-edited therapy will not be universally applicable in the near future for several reasons: Eligibility is limited to patients who meet specific medical and immune system criteria. Cost is prohibitive for many health systems and will likely be reserved for high-risk or difficult-to-treat cases. Durability of results is still uncertain; more data is needed on long-term outcomes and safety. Global accessibility is limited, particularly in low- and middle-income countries. Health systems must consider cost-effectiveness and budget impact before authorizing widespread adoption. Recent breakthroughs — such as the survival of transplanted allogeneic beta cells without immunosuppression — are encouraging. However, they represent early scientific progress, not yet a scalable solution. Conclusion Gene-edited cell therapies offer one of the most exciting frontiers in the treatment of Type 1 diabetes. The idea of replacing insulin injections with a one-time or limited course of treatment is revolutionary. However, the high cost, limited availability, and unresolved clinical questions mean these therapies will not become the cure for everyone — at least not yet. For the foreseeable future, insulin remains the only practical and widely accessible option. Policymakers, researchers, and health systems must work together to ensure that as these therapies mature, they become not just effective — but also equitable and affordable.
© 2000-2025 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9